## Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes

Wendy S. Bibeau, PhD, MEd; Haoda Fu, PhD; April D. Taylor, MSN, CNS, BC-ADM; and Anita Y.M. Kwan, MSc

#### ABSTRACT

BACKGROUND: Medication adherence is pivotal for the successful treatment of diabetes. However, medication adherence remains a major concern, as nonadherence is associated with poor health outcomes. Studies have indicated that increasing patients' share of medication costs significantly reduces adherence. Little is known about a potential out-of-pocket (00P) cost threshold where substantial reduction in adherence may occur.

**OBJECTIVE:** To examine the impact of diabetes OOP pharmacy costs on antihyperglycemic medication adherence and identify the potential threshold at which significant reduction in adherence may occur among patients with type 2 diabetes mellitus (T2DM).

METHODS: This was an observational, retrospective cohort study using longitudinal U.S. pharmacy and medical claims data from the IMS Health Medical Claims (Dx) database. Patients with T2DM who initiated therapy with a branded antihyperglycemic medication during the index period (January 1, 2011, to December 31, 2011) and had 3 years of follow-up data were included. The primary outcome was adherence to antihyperglycemic medications, measured as the number of days covered. Propensity scores were calculated using baseline sociodemographic and clinical characteristics to control for potential confounding factors. Four strata were created based on mean propensity scores. Across each stratum, patients were assigned to 5 diabetes OOP pharmacy (including generics) cost levels: \$0-\$10, \$11-\$40, \$41-\$50, \$51-\$75, and >\$75. Multivariate regression models were used to estimate association of diabetes OOP pharmacy costs and adherence for each stratum. Sensitivity analyses were conducted to assess the impact of total OOP pharmacy costs and index drug category 00P costs on adherence.

**RESULTS:** A total of 15,416 patients were assessed. Across each stratum in the diabetes OOP pharmacy cost analysis group, mean patient age ranged from 52.3 to 56.1 years, mean number of antihyperglycemic medication classes ranged from 1.5 to 3.2, and mean household income ranged from \$60,763 to \$79,373. Most patients used a commercial plan (55%-85%). The propensity-stratified multivariate regression model revealed an overall negative relationship between diabetes OOP pharmacy costs and adherence across several OOP cost levels. Diabetes OOP pharmacy cost level \$51-\$75 appeared as the threshold at which adherence reduced significantly (77-78 fewer days of coverage over 3 years of follow-up; P<0.05) when compared with the lowest OOP costs (\$0-\$10) across all strata. Adherence reduced further (99-145 fewer days of coverage; P<0.0001) for the higher diabetes 00P pharmacy cost levels (>\$75) when compared with the lowest OOP cost levels. Sensitivity analyses with total OOP pharmacy costs and index drug category OOP costs revealed negative association with adherence across all strata.

**CONCLUSIONS:** Diabetes OOP pharmacy cost was negatively associated with patient adherence, and a potential OOP cost threshold (\$51-\$75) was identified at which adherence reduced significantly. The study findings may be beneficial in informing the design of health care plans to achieve optimal adherence and improve disease management in patients with T2DM.

J Manag Care Spec Pharm. 2016;22(11):1338-47

Copyright©2016, Academy of Managed Care Pharmacy. All rights reserved.

#### What is already known about this subject

- Adherence to therapy is a critical component in the successful management of diabetes. However, studies indicate that less than 50% of patients achieve glycemic goals, which may be attributable to low medication adherence in patients with type 2 diabetes mellitus (TD2M).
- Medication nonadherence has been reported to lead to poor clinical outcomes, high resource utilization, and increased costs in patients with diabetes. Out-of-pocket (OOP) costs have been shown to be negatively associated with medication adherence in patients with diabetes.
- New strategies that shift costs to the patient in order to drive patient awareness about cost of care are, in part, responsible for the increase in patient OOP costs. However, studies suggest that switching to a health care plan that includes modest drug copays may not reduce medication use or lead to reduced adherence for chronic diseases.

#### What this study adds

- This study provides contemporary evidence that antihyperglycemic medication adherence differs by OOP cost levels in patients with T2DM.
- The study findings indicate that there is a threshold at which OOP costs become a substantial barrier to attaining antihyperglycemic medication adherence. Diabetes OOP pharmacy cost level \$51-\$75 was identified as the potential threshold at which significant reduction in adherence was observed. Sensitivity analysis revealed a higher threshold (OOP cost levels \$91-\$150) for total OOP pharmacy costs.
- These results can be used to inform plan designs and tier structure to ensure copays do not negatively and substantially affect medication adherence and thereby help to attain optimal adherence and reduce overall health care expenditures in patients with diabetes.

Diabetes mellitus is a complex, multifactorial disease that affects approximately 29 million people in the United States.<sup>1</sup> Diabetes and associated complications are expected to be the seventh leading cause of death by 2030.<sup>2</sup> Type 2 diabetes mellitus (T2DM) is the most common type and accounts for 90%-95% of all diagnosed cases.<sup>1</sup> Lifestyle changes are recommended as the first-line therapy for patients

1338 Journal of Managed Care & Specialty Pharmacy JMCP November 2016 Vol. 22, No. 11 www.jmcp.org

with T2DM, and oral antihyperglycemic medications, with or without insulin, are used if adequate glycemic control is not achieved or maintained by lifestyle changes.<sup>3</sup> A critical component in the successful management of diabetes is adherence to therapy.<sup>4</sup> However, studies indicate that less than 50% of patients achieve glycemic goals, which may be attributable, in part, to low adherence to therapies.<sup>5</sup>

Medication adherence is a major concern to providers, health care systems, and payers due to the increasing evidence that medication nonadherence is pervasive<sup>6</sup> and associated with adverse health outcomes and high resource utilization (e.g., hospitalizations, emergency department [ED] visits, etc.) and costs.<sup>7</sup> Medication nonadherence is responsible for substantial medication-related hospital admissions, ranging from 33% to 69%,<sup>8</sup> and the suboptimal rates of medication adherence<sup>9</sup> are estimated to cost the U.S. health care system between \$100 billion and \$300 billion annually.<sup>10</sup> The medical cost burden of the least-adherent patients with T2DM (\$21,421) is nearly 3 times higher than the most-adherent patients with T2DM (\$7,692).<sup>11</sup>

Conversely, evidence suggests that individuals with better medication adherence have better health outcomes and lower rates of health care resource utilization. It has been estimated that improved adherence to antihyperglycemic medications could avoid 699,000 ED visits and 341,000 hospitalizations annually.<sup>12</sup> Also, it is estimated that every additional dollar spent on adhering to a prescribed medication would reduce total health care costs by \$6.7 in patients with diabetes,<sup>13</sup> and improved adherence could potentially lead to annual health care savings of up to \$8.3 billion in the United States.<sup>12</sup>

With continual increases in health care spending,<sup>14</sup> strategies are being used to curb the overuse of unnecessary medications and shift costs to the patient, such as increase in patient copayments and coinsurance, increase in formulary listing restrictions, and mandatory substitution of branded products with less expensive generics.<sup>15</sup> A 2015 annual census of U.S. health insurance companies has shown that enrollment in health savings account/high-deductible health plans has almost doubled in the last 5 years.<sup>16</sup> These strategies are partly the reason for the increase in patient OOP costs, which increased by 1.3% to \$329.8 billion in 2014 or 11% of total national health expenditures in 2014.<sup>14</sup> Unfortunately, these strategies to reduce medication use may be counterproductive, as studies have indicated that increasing patient share of medication costs is significantly associated with a decrease in adherence.17

However, a study has reported that switching to a health care plan that includes modest drug copays may not reduce medication use or lead to reduced adherence for chronic diseases.<sup>18</sup> Therefore, it is essential for managed care decision makers to identify the point at which additional OOP costs adversely affect medication adherence.<sup>15</sup> Although a few studies have assessed

DOCKE

the impact of patient copay levels on adherence in patients with T2DM,<sup>19-21</sup> the threshold of OOP pharmacy costs that leads to significant reduction in adherence remains unclear. Also, the increasing trend of enrollment in high-deductible health plans in recent years indicates a need for ongoing research on the association of OOP costs and adherence.

The objective of this study was to examine the impact of diabetes OOP pharmacy costs on adherence and identify the threshold of diabetes OOP pharmacy costs at which copays become a substantial barrier to attaining antihyperglycemic medication adherence, regardless of income and sociodemographic and clinical characteristics.

#### Methods

#### **Data Source**

This study used longitudinal pharmacy and medical claims data from the IMS/Amundsen database. The IMS Health Medical Claims (Dx) database is a longitudinal dataset that captures information about patients' medical diagnoses, procedures, laboratory investigations, and other related medical claims activity from full-time office-based physicians across the United States.<sup>22</sup> This dataset was used to identify other diagnosed comorbidities for the cohort of patients with diabetes and subsequently assign the appropriate number of points for the chronic disease score (CDS)<sup>23</sup> and adapted diabetes complications severity index (aDCSI).<sup>24</sup>

In addition, data from the formulary impact analyzer (FIA) were used to identify OOP costs for each claim. The FIA is a transactional claim dataset derived from the interaction and information passing between pharmacy outlets and payer adjudication processes. The FIA is sourced from retail and mailorder pharmacies and is a nonprojected dataset (i.e., data are not projected up to estimate the total market, thereby allowing patient longitudinal analyses to be conducted) representing approximately 50% of claim volume for the diabetes market. Each claim was mapped to a de-identified patient in the IMS system using a proprietary and patented approach, enabling these FIA patients to be linked to the IMS system. Finally, the claims data were cross-matched with sociodemographic variables through partnership with Experian, the global information services company, and the impact of these variables on the outcomes of interest was evaluated.

#### **Study Design**

This study was an observational, retrospective cohort analysis of patients with T2DM aged 18-85 years who initiated 1 or more branded antihyperglycemic products within selected Uniform System of Classification categories (Appendix A, available in online article) during the index period (January 1, 2011, to December 31, 2011). Patients should have had (a) at least 2 claims with a T2DM diagnosis (*International Classification of Diseases, Ninth Revision, Clinical Modification* [ICD-9-CM] 250.x0,

www.jmcp.org Vol. 22, No. 11 November 2016 *JMCP* Journal of Managed Care & Specialty Pharmacy 1339 Novo Nordisk Exhibit 2521

250.x2) on 2 dates during the pre-index period (6 months before the index date), (b)  $\geq$ 6 months' continuous eligibility in the pre-index period, and (c)  $\geq$ 12 months' continuous eligibility during the post-index period (3-year follow-up period). Patients with claims for a type 1 diabetes mellitus (ICD-9-CM 250.x1, 250.x3) or gestational diabetes (ICD-9-CM 648.8x) diagnosis during the pre-index period were excluded.

#### Measures

Demographic characteristics were summarized for the target population, including age and sex at index period, and income, level of education, geographic location, marital status, and insurance plan type (commercial, Medicare Part D) at index and follow-up periods. Clinical variables such as CDS (score ranging from 0 to 36, with higher scores indicating poorer outcomes),<sup>23</sup> aDCSI (score ranging from 0 to 13, with higher scores indicating increased risk of complications),<sup>24</sup> and targeted comorbidities of interest were captured at index period (Appendix B, available in online article).

The primary outcome measure was antihyperglycemic medication adherence, which was measured by the number of days covered during the follow-up period from January 1, 2012, to December 31, 2014. The number of days covered was defined as the number of days in the follow-up period during which the index medication was determined to be in hand based on the pharmacy claim fill date plus days supply. The follow-up period was 3 years for all patients.

The first-year mode copay was used to determine patient OOP costs for each drug category. Diabetes OOP pharmacy costs were calculated by adding all first-year mode copay amounts across all diabetes medications including generics. On the basis of the data retrieved and the most logical or frequently observed cut points, patients were assigned to 5 diabetes OOP pharmacy cost levels based on monthly OOP costs: \$0-\$10, \$11-\$40, \$41-\$50, \$51-\$75, and > \$75. Patients starting therapy in multiple index drug categories were assigned to cost cohorts in all the drug categories in which they initiated therapy during the index period, but the overall OOP costs were calculated at the patient level. The impact of diabetes OOP pharmacy costs on adherence was measured for patients for the OOP cost levels identified. For all patients, adherence as a function of diabetes OOP pharmacy costs was observed at the patient level, and patients were tracked over the follow-up period to determine the number of days covered.

#### **Statistical Analysis**

DOCKE

The association of diabetes OOP pharmacy costs and adherence was assessed using a propensity-stratified combined impact model. A logistic regression analysis was conducted wherein the dependent variable was OOP medication cost >\$35; the dependent variable, OOP medication cost >\$35, was identified based on a generally linear trend with a commonly observed point of inflection of about \$35.<sup>25</sup> Confounders were selected based on Pearson's correlation, and those with the highest coefficients were included. Confounders included age, income, number of diabetes medication classes, total number of diabetes medications, CDS, number of all medication classes, total number of all medications, marital status, and type of insurance.

Propensity scores were calculated to estimate the probability of OOP medication costs >\$35 using baseline sociodemographic and clinical characteristics. To minimize the impact of confounding variables, patients were divided into 4 strata based on Tukey's Five Number Summary. Matching was not done, and propensity score stratification was used for adjustment in the analysis. A multivariate basic regression model was conducted to estimate the association of diabetes OOP pharmacy costs and antihyperglycemic medication adherence for each stratum. Diabetes OOP pharmacy costs and the stratifications resulting from the propensity stratification were the independent variables, whereas total number of days covered for diabetes medications during the 3-year follow-up was the dependent variable in the multivariate analysis.

Variables missing on more than 10% of the claims transactions were not included in the analyses. However, if a variable was considered crucial to an analysis and the volume became an issue per the rule above, claims with populated fields were included in the analysis.

#### **Sensitivity Analysis**

Patients with diabetes are at a high risk of coexisting medical conditions and may require multiple medications to manage not only hyperglycemia but also associated comorbidities, such as dyslipidemia, hypertension, and depression.<sup>26</sup> Therefore, a sensitivity analysis was conducted to assess the impact of total OOP pharmacy costs on adherence. The total OOP pharmacy costs were calculated by adding first-year mode copay amounts across all therapy area medications, including generics. Patients were assigned to 6 total OOP pharmacy cost cohorts based on monthly OOP costs: \$0-\$30, \$31-\$60, \$61-\$90, \$91-\$150, \$151-\$200, and >\$200. In addition, the association of the index diabetes medication (only 1 antihyperglycemic medication) OOP costs and adherence was also assessed across several monthly OOP cost levels (\$0-\$10, \$11-\$40, \$41-\$50, \$51-\$75, and >\$75) in the sensitivity analysis to account for the effect of patients' characteristics at index period.

#### Results

At the beginning of the study, more than 6.5 million patients with diabetes were identified. After applying the inclusion and exclusion criteria, the majority of the patients were excluded because they had not initiated an index drug category treatment during the index period. On average, the index drug categories selected were more expensive than other agents such

1340 Journal of Managed Care & Specialty Pharmacy JMCP November 2016 Vol. 22, No. 11 www.jmcp.org



as metformin and sulfonylurea that were not included as index drug categories, but patients had different insurance coverages that allowed some patients to fill the selected agents at little to no cost, thus allowing a variety of costs to be included in the assessment of adherence. Approximately 116,975 patients with therapy initiation in 2011 and pharmacy claims data for the entire 3-year study period were eligible for the study. Considering patients whose cost information and socioeconomic data were available, the final sample size for each model was 15,416 patients (Figure 1).

#### **Baseline Characteristics**

DOCKE

The categorization of the 4 strata based on the probability of having a copay of >\$35 is outlined in Table 1. Stratum 1 had the lowest probability of high OOP costs, whereas stratum 4 had the highest probability of high OOP costs.

At the index period, although significant differences were observed for some covariates, overall the covariates were balanced across the 2 OOP cost groups (>35 and  $\leq$ 35). The

TABLE 1 Copay Stratification Based on the Probability of OOP Medication Costs > \$35							
		Propensity Scores (%)					
Stratum	Ν	Average	Minimum	Maximum			
1	3,854	3.0	0.1	5.4			
2	3,854	7.8	5.4	10.1			
3	3,854	13.5	10.1	18.1			
4	3,854	29.5	18.1	90.0			
OOP = out-of-pocket.							

number of diabetes medications and diabetes therapy classes used at index period were similar across all 4 strata (Table 2A). Across each stratum, the mean patient age ranged from 46.6 to 61.6 years, mean CDS ranged from 5.4 to 7.0, mean number of diabetes medication classes ranged from 1.9 to 2.4, and mean household income ranged from \$62,893 to \$77,028. Most patients were married (mean range, 62%-98%) and some used

www.jmcp.org Vol. 22, No. 11 November 2016 *JMCP* Journal of Managed Care & Specialty Pharmacy 1341 Novo Nordisk Exhibit 2521

TABLE 2

#### **Demographic and Clinical Characteristics**

Confounders	Stratum 1 N=3,854	Stratum 2 N=3,854	Stratum 3 N=3,854	Stratum 4 N=3,854			
A. Characteristics at Index Period							
Age (years), mean±SD	46.6±15.4a	54.1±12.1	$57.3 \pm 12.2^{b}$	61.6±13.0			
Income, \$, mean ± SD	64,377±48,174	75,941±47,609	77,028±48,897	62,893±45,947 <sup>a</sup>			
Diabetes medication class, <sup>c</sup> mean ± SD	2.4±1.1a	2.2±0.9	1.9±0.9	$1.9 \pm 0.9a$			
Diabetes therapies, mean±SD	2.8±1.1	$2.5 \pm 1.0^{a}$	2.1±1.0	$2.1 \pm 1.0^{a}$			
CDS, mean±SD	7.0±3.2ª	6.3±2.9a	$5.4 \pm 2.5$	$6.2 \pm 3.0^{a}$			
Total medication class, <sup>d</sup> mean±SD	9.1 ± 3.9 <sup>a</sup>	$7.6 \pm 3.4^{a}$	5.7±3.0	$6.7 \pm 3.8^{a}$			
Total therapies, mean ± SD	9.6±4.0ª	8.1±3.4a	6.2±3.1	7.1 ± 3.9a			
Married, %	62	96	95	98			
Commercial, %	72	98	94	30 <sup>a</sup>			
Part D, %	0	2 <sup>a</sup>	5 <sup>a</sup>	60			
Medicaid, %	28	0	0	0			
B. Characteristics of the Diabetes OOP Pharmacy Costs Group							
Age (years), mean±SD	52.3±15.2	$55.6 \pm 15.2^{b}$	56.1 ± 14.0	55.5±12.4			
Income, \$, mean±SD	60,763±43,577	$67,787 \pm 46,504^{b}$	$72,312 \pm 48,630^{b}$	79,373±51,444			
Diabetes medication class, <sup>c</sup> mean ± SD	$1.5 \pm 0.8^{a}$	$1.6 \pm 0.6$	$2.2 \pm 0.5$	$3.2 \pm 0.7$			
Diabetes therapies, mean±SD	$1.8 \pm 0.9^{a}$	$1.8 \pm 0.8$	$2.4 \pm 0.7$	$3.4 \pm 0.9$			
CDS, mean±SD	6.5±3.2a	6.0±3.0	$6.3\pm2.9^{b}$	$6.1\pm2.7^{b}$			
Total medication class, <sup>d</sup> mean±SD	6.8±4.3 <sup>a</sup>	$6.5 \pm 3.5^{b}$	$7.5 \pm 3.5^{a}$	$8.3 \pm 3.5^{a}$			
Total therapies, mean ± SD	7.4 ± 4.3a	6.9±3.6	$7.9 \pm 3.6^{a}$	$8.8 \pm 3.6^{a}$			
Married, %	76	89	92	94			
Commercial, %	55	76 <sup>b</sup>	78ª	85			
Part D, %	17	23	18	9a			
Medicaid, %	28	0	0	0			

Note: Patients were divided into 4 strata based on Tukey's Five Number Summary to minimize the impact of confounding variables. P values indicate comparison of ≤\$35 OOP cost group versus > \$35 OOP cost group.

<sup>a</sup>P<0.0001

bP<0.05

DOCKE

Diabetes medication class is defined as the number of diabetes drug categories (including injectables) used by a patient simultaneously during the index period. <sup>d</sup>Total medication class is defined as the number of all therapy area drug categories used by a patient simultaneously during the index period. CDS = chronic disease score; OOP = out-of-pocket; SD = standard deviation.

a commercial plan (mean range, 30%-98%). Stratum 1 had the lowest mean age (46.6 years) and highest CDS (7.0) and was the only group with patients covered by a Medicaid plan (28%). Stratum 2 had the highest proportion of patients in a commercial plan (98%). Stratum 3 had the highest mean household income (\$77,028), lowest CDS (5.4), and second-highest proportion of patients in a commercial plan (94%). Stratum 4 had the lowest mean household income (\$62,893) and the highest proportion of patients in a Medicare Part D plan (60%).

Similar to the index period, the covariates were balanced across the 2 OOP cost groups (>\$35 and  $\leq$ \$35) for the diabetes OOP pharmacy cost analysis group, although significant differences were observed for some covariates. The mean patient age ranged from 52.3 to 56.1 years, mean CDS ranged from 6.0 to 6.5, mean number of diabetes medication classes ranged from 1.5 to 3.2, and mean household income ranged from \$60,763 to \$79,373 (Table 2B). Most patients were married (mean range, 76%-94%) and used a commercial plan (mean range, 55%-85%). Stratum 1 had the lowest mean household income (\$60,763) and

was the only group with patients covered by a Medicaid plan (28%). Stratum 2 reported the highest proportion of patients in a Medicare Part D plan (23%). Stratum 3 had the second-highest number of diabetes medication classes (2.2) and secondhighest proportion of patients in a commercial plan (78%). Stratum 4 had the highest mean household income (\$79,373), highest total number of diabetes medication classes (3.2), and highest proportion of patients in a commercial plan (85%).

#### **OOP Pharmacy Costs and Adherence**

In the unadjusted analysis for the overall population, antihyperglycemic medication adherence decreased as the diabetes OOP pharmacy costs increased. For patients on basal insulin, a continuous decrease in antihyperglycemic medication adherence was observed for diabetes OOP pharmacy cost levels  $\geq$  \$75, with patients in the diabetes OOP pharmacy cost levels \$75-\$99.99 reporting 464 days of antihyperglycemic medication coverage compared with 508 days in the lowest diabetes OOP pharmacy cost levels (\$0-\$9.99). Similarly, patients on

1342 Journal of Managed Care & Specialty Pharmacy JMCP November 2016 Vol. 22, No. 11 www.jmcp.org

Novo Nordisk Exhibit 2521

# DOCKET



## Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

